ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.04
0.60%
US Tech 100
17,446.00
2.17%
S&P 500
5,127.79
1.26%
US Dollar vs CAD
1.3685
-0.05%
Bitcoin
64,163.50
0.26%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Okyo Pharma Limited (OKYO)

  7. Okyo Pharma Limited (OKYO) News

OKYO

Okyo Pharma (OKYO)

Okyo Pharma Limited
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:OKYO
DateTimeSourceHeadlineSymbolCompany
04/30/20246:00AMUK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)LSE:OKYOOkyo Pharma Limited
04/08/20246:00PMUK RegulatoryOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024LSE:OKYOOkyo Pharma Limited
04/02/20246:00AMUK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryLSE:OKYOOkyo Pharma Limited
03/22/20246:00AMUK RegulatoryOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101LSE:OKYOOkyo Pharma Limited
03/21/20246:00AMUK RegulatoryOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialLSE:OKYOOkyo Pharma Limited
03/20/20246:00AMUK RegulatoryOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventLSE:OKYOOkyo Pharma Limited
02/09/20246:36AMInvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
02/09/20246:00AMUK RegulatoryOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
01/31/20246:00AMUK RegulatoryOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardLSE:OKYOOkyo Pharma Limited
05/22/20232:15AMUK RegulatoryOKYO Pharma Limited London Stock Exchange DelistingLSE:OKYOOkyo Pharma Limited
05/22/20232:00AMUK RegulatoryLondon Stock Exchange Notice Cancellation - OKYO PHARMA LIMITEDLSE:OKYOOkyo Pharma Limited
05/19/20235:22AMAlliance NewsAlliance NewsIN BRIEF: Okyo Pharma to move shares to New York with London delistingLSE:OKYOOkyo Pharma Limited
05/19/20232:00AMRNS Non-RegulatoryOKYO Pharma Limited ADS Program collapseLSE:OKYOOkyo Pharma Limited
05/15/20231:00AMUK RegulatoryOKYO Pharma Limited Change of Record Time and Last Day of DealingsLSE:OKYOOkyo Pharma Limited
05/11/20238:27AMAlliance NewsAlliance NewsIN BRIEF: Okyo Pharma delays delisting from London trading to May 22LSE:OKYOOkyo Pharma Limited
05/11/20236:00AMRNS Non-RegulatoryOKYO Pharma Limited Webull Corporate Communications Service PlatformLSE:OKYOOkyo Pharma Limited
05/11/20231:00AMUK RegulatoryOKYO Pharma Limited Change of Delisting Date to 22 May 2023LSE:OKYOOkyo Pharma Limited
05/03/20237:00AMUK RegulatoryOKYO Pharma Limited Result of MeetingLSE:OKYOOkyo Pharma Limited
05/03/20231:00AMRNS Non-RegulatoryOKYO Pharma Limited Presentation on OK-101 at ASCRSLSE:OKYOOkyo Pharma Limited
05/02/20232:16PMAlliance NewsAlliance NewsTRADING UPDATES: Knights Group buys St James Law and Baines WilsonLSE:OKYOOkyo Pharma Limited
05/02/20231:00AMUK RegulatoryOKYO Pharma Limited First-Patient First-Visit for Phase 2 TrialLSE:OKYOOkyo Pharma Limited
04/25/202310:19AMAlliance NewsAlliance NewsTRADING UPDATES: Eckoh expects profit up; LXi REIT refinances facilityLSE:OKYOOkyo Pharma Limited
04/25/20231:00AMUK RegulatoryOKYO Pharma Limited Activation of First Clinical Trial Site in the U.SLSE:OKYOOkyo Pharma Limited
04/05/20231:00AMUK RegulatoryOKYO Pharma Limited NOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATIONLSE:OKYOOkyo Pharma Limited
04/04/20233:08AMAlliance NewsAlliance NewsOkyo Pharma applies to delist from London Stock Exchange due to costsLSE:OKYOOkyo Pharma Limited
04/04/20231:00AMUK RegulatoryOKYO Pharma Limited Notice Of Intention To Delist From The LSELSE:OKYOOkyo Pharma Limited
03/30/20231:00AMUK RegulatoryOKYO Pharma Limited Director Acquires SharesLSE:OKYOOkyo Pharma Limited
03/29/20231:00AMUK RegulatoryOKYO Pharma Limited Director acquires sharesLSE:OKYOOkyo Pharma Limited
03/24/20232:00AMUK RegulatoryOKYO Pharma Limited Director/PDMR ShareholdingLSE:OKYOOkyo Pharma Limited
03/16/20232:01AMRNS Non-RegulatoryOKYO Pharma Limited Listing of Trial on the ClinicalTrials.gov WebsiteLSE:OKYOOkyo Pharma Limited
 Showing the most relevant articles for your search:LSE:OKYO

Your Recent History

USOTC
TGLO
TheGlobe com (PK)
USOTC
CYDY
CytoDyn (QB)
USOTC
VPLM
Voip Pal Com (QB)
COIN
SHIBUSD
SHIBA INU
USOTC
BLLB
Bell Buckle (PK)
USOTC
IFUS
Impact Fusion (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
SPZI
Spooz (PK)
NASDAQ
COOP
Mr Cooper
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
NASDAQ
AMRN
Amarin
NASDAQ
AGBA
AGBA
USOTC
CGAC
Code Green Apparel (PK)
NASDAQ
AVXL
Anavex Life Sciences
NASDAQ
LWLG
Lightwave Logic
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved